Blood-Filtering therapy may tame rare brain inflammation in children
NCT ID NCT03274375
First seen Jul 01, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This trial investigates whether a blood-filtering procedure called immunoadsorption (IA), combined with the drug rituximab, can improve neurological function in children aged 0-18 with severe anti-NMDAR encephalitis. Participants receive 10 IA sessions over 28 days plus weekly rituximab for four weeks. The study measures changes in disability scores to see if the treatment helps reduce brain inflammation and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immunoadsorption therapy (IA) and rituximab
- What this could lead to
- If successful, this approach could offer a more effective way to control severe anti-NMDAR encephalitis in children, potentially reducing long-term disability.
- What could go wrong
- This is a small Phase 2 study with only 20 participants, so results may not apply broadly. The treatment involves risks from both immunoadsorption and rituximab, including infection and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NMDAR ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants-Malades
Paris, Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.